There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status
We aim ed to compare clinical outcomes , health-related quality of life ( HRQOL ) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder . This double-blind , r and omized controlled trial , comparing flexible dosing of olanzapine ( 5–20 mg/day , n = 234 ) to haloperidol ( 3–15 mg/day , n = 219 ) , consisted of a 6-week acute phase , followed by a 6-week continuation phase . Symptomatic remission rates were similar for olanzapine- and haloperidol-treated patients at weeks 6 and 12 . At week 6 , significant changes in five dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey ( SF-36 ) [ general health ( P = 0.010 ) , physical functioning ( P < 0.001 ) , role limitations due to physical problems ( P < 0.001 ) , social functioning ( P < 0.05 ) and vitality ( P < 0.01 ) ] and the SF-36 physical components summary score were found in favour of olanzapine compared to haloperidol . At week 12 , olanzapine treatment maintained the significantly favourable HRQOL changes . At the end of week 12 , patients on olanzapine showed significantly greater improvement than haloperidol  in work activities impairment and household activities impairment scores on the Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation ( SLICE/LIFE ) activities impairment scores . Subgroup analyses revealed that olanzapine treatment significantly increased a proportion of employed patients and their weekly paid working hours . In conclusion , compared to haloperidol , olanzapine treatment was comparably effective in the remission of bipolar mania and significantly improved HRQOL and work status in patients with bipolar I disorder
There is some evidence that haloperidol is an effective treatment for  acute mania .
From the limited data available , there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone .
Some evidence suggests that haloperidol could be less effective than aripiprazole .
BACKGROUND The main objectives in treating mania are to control dangerous behaviour , reduce suicide , produce appropriate acute sedation and shorten the episode of mood disturbance .
Among different drugs , haloperidol has for many years been used in treating psychotic patients , but it has a troublesome side effect profile .
OBJECTIVES To assess the effects of haloperidol for the treatment of mania in comparison with placebo or other active drugs , either as monotherapy or add-on treatment .